Image 1 of 4
Image 2 of 4
Image 3 of 4
Image 4 of 4
Packaging & supply options
Your format, your way.
The same research peptide, with a choice of accessories and supply formats. Here’s what each option includes.
BAC water
Vial kit
Lyophilised peptide vial with separately packaged, complimentary BAC water.
BAC water + syringes
Syringe kit
Lyophilised peptide vial, BAC water and syringes.
BAC water + pen
Injection pen kit
Lyophilised peptide vial, BAC water and an injection pen.
Pen + pen needles
Reconstituted pen
VIETNAM ONLYPeptide solution supplied in a pen at the stated concentration, with pen needles.
For laboratory research only. Not for human or veterinary use.
Everform Pharma · Compound profile
Retatrutide.
Three pathways. One metabolic story.
Explore triple-receptor signalling and the research connecting body weight, glucose regulation and liver fat.
What is retatrutide?
Retatrutide, also known by its development code LY3437943, is a single synthetic peptide designed to activate three hormone receptors: GLP-1, GIP and glucagon. That combination makes it a distinctive subject in body-weight and metabolic research. [1]
Its appeal to researchers is the opportunity to examine several linked aspects of energy balance within one molecule, rather than treating appetite, glucose control and metabolism as separate questions.
How do the three pathways work together?
GLP-1 and GIP are incretin hormones involved in the response to food. Glucagon is a separate hormone with an important role in fuel regulation. Retatrutide combines activity at all three receptor systems. [1]
GLP-1
A pathway involved in appetite, food intake and glucose-dependent insulin release.
GIP
An incretin pathway contributing to nutrient-responsive insulin signalling.
GLUCAGON
A fuel-regulation pathway explored for its contribution to energy expenditure.
In the discovery programme, mouse experiments linked reduced food intake with increased energy expenditure. The energy-expenditure finding came from that experimental setting; it should not be treated as a measured resting-metabolic-rate result for every person. [1]
Main research areas
Retatrutide research spans several connected metabolic outcomes. Each study measures a specific question in a defined population.
| Research area | What studies examine |
|---|---|
| Body weight | Average weight changes over time in adults with obesity or overweight and related conditions. [2] |
| Glucose regulation | HbA1c and body-weight changes in adults with type 2 diabetes. [3] |
| Liver fat | Changes in liver fat measured by MRI in participants with metabolic dysfunction-associated steatotic liver disease. [4] |
| Energy balance | How food intake and energy expenditure contribute to the response in preclinical models. [1] |
These research areas describe study outcomes, not guaranteed effects of an Everform product.
What published findings show
Body-weight research: A phase 2 trial enrolled 338 adults with obesity or overweight and a weight-related condition. At 48 weeks, the highest-dose study group had an estimated average body-weight reduction of 24.2%, compared with 2.1% in the placebo group. These are group averages from a controlled trial, not predictions for an individual. [2]
Glucose regulation: A separate phase 2 trial in adults with type 2 diabetes found improvements in HbA1c and body weight. Results differed between treatment groups, which is why the participant population and study design matter when reading headline figures. [3]
Liver-fat research: A 98-participant substudy measured liver fat using MRI. Retatrutide groups showed reductions in liver fat compared with placebo. This imaging result does not by itself establish reversal of liver scarring or long-term liver outcomes. [4]
These selected publications concern clinical-trial material and monitored participants. They do not establish equivalent quality, safety or outcomes for an Everform research vial or pen.
Safety findings also form part of the picture. Gastrointestinal adverse effects were common in the phase 2 obesity trial, and increases in heart rate were observed. Benefits should therefore be read alongside the study’s safety results. [2]
Retatrutide remains investigational. The clinical programme has progressed to phase 3; the studies above provide a focused introduction rather than a complete review of every later trial. [5]
The Everform product, at a glance
CompoundRetatrutide
Labelled vial amount20 mg
Base formatLyophilised peptide powder
Supply optionsSee the format guide above
Everform Pharma is based in Da Nang, Vietnam. Use the product selector to choose an available supply format. Complimentary BAC water is included with every order.
Explore Your format, your way →
Check the product label for the full REF, expiry date and storage conditions. The transport-package security sticker repeats the product identifier and should match the vial or pen inside. Match the full REF to the relevant documentation.
Identity, chromatographic purity and measured peptide content answer different questions on a COA. A purity percentage alone does not establish the amount of peptide per vial.
Common questions
What does “triple agonist” mean?
It means one molecule activates three receptor types. For retatrutide, these are GLP-1, GIP and glucagon receptors. It does not mean three separate peptides are mixed together. [1]
Does 24.2% mean everyone loses that amount?
No. It was an estimated group-average result at 48 weeks in one arm of a particular phase 2 trial. Individual responses varied, and the figure is not a product guarantee. [2]
Does “20 mg” describe a dose?
No. It describes the labelled amount of peptide in the vial, not a recommended dose or administration instruction.
Can body-weight loss be described as pure fat loss?
No. Total body weight and body composition are different measurements. A weight-loss percentage should not be relabelled as a fat-loss percentage or a guarantee of muscle preservation.
Where should I check storage and product identification?
Follow the storage conditions on your actual product label. Confirm that the package sticker matches the vial or pen and use the full REF when requesting matching documentation.
References
Everform Pharma · Da Nang, Vietnam
Educational product information.
For laboratory research only.
Not for human or veterinary use.
